Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Abstract
Recently, adeno-associated virus (AAV)-mediated gene therapies have attracted clinical interest for treating neurodegenerative diseases including spinal muscular atrophy (SMA), Canavan disease (CD), Parkinson’s disease (PD), and Friedreich’s ataxia (FA). The influx of clinical findings led to the first approved gene therapy for neurodegenerative disorders in 2019 and highlighted new safety concerns for patients. Large doses of systemically administered AAV stimulate host immune responses, resulting in anti-capsid and anti-transgene immunity with implications for transgene expression, treatment longevity, and patient safety. Delivering lower doses directly to the central nervous system (CNS) is a promising alternative, resulting in higher transgene expression with decreased immune responses. However, neuroinflammatory responses after CNS-targeted delivery of AAV are a critical concern. Reported signs of AAV-associated neuroinflammation in preclinical studies include dorsal root ganglion (DRG) and spinal cord pathology with mononuclear cell infiltration. In this review, we discuss ways to manage neuroinflammation, including choice of AAV capsid serotypes, CNS-targeting routes of delivery, genetic modifications to the vector and/or transgene, and adding immunosuppressive strategies to clinical protocols. As additional gene therapies for neurodegenerative diseases enter clinics, tracking biomarkers of neuroinflammation will be important for understanding the impact immune reactions can have on treatment safety and efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR2 detects the capsid proteins of extracellular viral particles, while TLR9 detects unmethylated CpG motifs within single-stranded viral DNA genomes present in endosomes (Perez et al., 2020; Wright, 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Perez et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, targeting the CNS through systemic administration remains challenging and requires vector doses 10-to 100-times higher than those used to target the liver 2,3 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since various AAV vectors themselves can increase both astrocytic and microglial markers (Ciron et al., 2006; Perez et al., 2020)”
From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Perez et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688 · cited 9×
“IT delivery of AAV is being tested across several clinical trials for SMA (NCT03381729), GAN (NCT03770572), MPS II (NCT0356604), and others.”
ResultInfluentialRetractedGlutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Similarly, differences in blood-brain barrier permeability between healthy animals and models of neurodegenerative diseases could result in different AAV biodistribution in the CNS, possibly contributing to discrepancies in translating findings from mouse models of disease into toxicology studies using larger, healthy…”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 3×
“Similarly, several preclinical studies and clinical trials [5,42] evaluated safety and efficacy data with no significant findings in support of the U.”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“Although the overall immunogenicity of AAV-based gene therapies is well characterized [6,7,9], immunogenicity from CNS-directed AAV delivery has not been widely investigated.”
BackgroundHow neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 1×
“Neuroinflammation is already a feature of many neurodegenerative diseases such as AD, Parkinson’s disease (PD), and multiple sclerosis (MS) [27].”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“In 2002, AAV 7, 8, 9 and rh10 were discovered in primates [55].”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“Of the common capsids currently available, AAV9 has emerged as the most widely used for CNS gene therapy applications due to its enhanced spread across CNS structures and its ability to penetrate the BBB even after peripheral administration in neonatal animals [61,62].”
BackgroundHumoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,245 · cited 1×
“In addition to managing systemically circulating antibodies, difficult to eliminate long-lived plasma cells may be reactivated by AAV treatment, secreting additional antibodies [97,98].”
BackgroundMicroglia initiate central nervous system innate and adaptive immune responses through multiple TLRs
Olson, J. K., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3916 · Cited by 1,215
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061 · cited 1×
“B serotype is an engineered capsid derived from AAV9 that showed remarkable CNS tropism in initial experiments in C57BL/6J mice [67].”
BackgroundInnate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034 · cited 2×
“B cell-mediated humoral responses can be initiated from the periphery or from within the CNS and in neurodegenerative disease, relevant antibodies are often present in both serum and cerebral spinal fluid (CSF) [24,28,29].”
BackgroundBroad Expression of Toll-Like Receptors in the Human Central Nervous System
Bsibsi, M., Ravid, R., Gveric, D., & van Noort, J. M. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.1013 · Cited by 999 · cited 1×
“TLR9 has been implicated in mediating the innate immune response to herpes simplex virus infection in the brain [92] as well as in pathobiology of several neurodegenerative diseases [91,93].”
BackgroundInflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966 · cited 1×
“For example, blood, CSF and neuroimaging are the most commonly used sources of biomarkers in neurodegeneration and neuroinflammation due to their non-invasive nature and versatility [32].”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
The myeloid cells of the central nervous system parenchyma
Ransohoff, R. M., & Cardona, A. E. (2010) · Nature · doi:10.1038/nature09615 · Cited by 804 · cited 1×
“B cell-mediated humoral responses can be initiated from the periphery or from within the CNS and in neurodegenerative disease, relevant antibodies are often present in both serum and cerebral spinal fluid (CSF) [24,28,29].”
BackgroundPivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits
Tang, S.-C., Arumugam, T. V., Xu, X., Cheng, A., Mughal, M. R., Jo, D. G., Lathia, J. D., Siler, D. A., Chigurupati, S., Ouyang, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702553104 · Cited by 779
The Role of Markers of Inflammation in Traumatic Brain Injury
Woodcock, T., & Morganti-Kossmann, M. C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00018 · Cited by 712
Regulation by 3′-Untranslated Regions
Mayr, C. (2017) · Annual Review of Genetics · doi:10.1146/annurev-genet-120116-024704 · Cited by 588 · cited 2×
“The incorporation of transgene-specific regulatory elements such as the endogenous transgene promoter and/or the 3’ untranslated region (UTR) [72,73] is a possible strategy for reducing neurotoxicity from overexpression or expression in non-target cell populations [74].”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“For example, AAV1 and 5 can transduce neurons and glial cells while AAV2 transduces neurons only but have limited spread within the CNS [54].”
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511 · cited 1×
“Of the common capsids currently available, AAV9 has emerged as the most widely used for CNS gene therapy applications due to its enhanced spread across CNS structures and its ability to penetrate the BBB even after peripheral administration in neonatal animals [61,62].”
BackgroundGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Hordeaux, J., Wang, Q., Katz, N., Buza, E. L., Bell, P., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.018 · Cited by 426 · cited 1×
“Follow up experiments determined that the exceptional neurotropic properties are exclusive to the C57BL/6J mouse strain and not recapitulated in other mouse strains or in NHP [68].”
BackgroundGray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420 · cited 1×
“Variations of this promoter have been characterized extensively and show robust expression throughout neuronal cell types in the CNS [71].”
BackgroundCearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409
Cultured astrocytes express toll‐like receptors for bacterial products
Bowman, C. C., Rasley, A., Tranguch, S. L., & Marriott, I. (2003) · Glia · doi:10.1002/glia.10256 · Cited by 395
LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide
Liu, Y., Walter, S., Stagi, M., Cherny, D., Letiembre, M., Schulz-Schaeffer, W., Heine, H., Penke, B., Neumann, H., & Fassbender, K. (2005) · Brain · doi:10.1093/brain/awh531 · Cited by 349 · cited 1×
“TLR9 has been implicated in mediating the innate immune response to herpes simplex virus infection in the brain [92] as well as in pathobiology of several neurodegenerative diseases [91,93].”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 1×
“TLR9 has been implicated in immune recognition of AAVs by binding to unmethylated CpG motifs in the AAV genome and activating signaling adaptor protein, myeloid differentiation primary response gene 88 (MyD88) [86].”
BackgroundImmunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
Muldoon, L. L., Alvarez, J. I., Begley, D. J., Boado, R. J., del Zoppo, G. J., Doolittle, N. D., Engelhardt, B., Hallenbeck, J. M., Lonser, R. R., Ohlfest, J. R., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.153 · Cited by 321 · cited 7×
“Of the common capsids currently available, AAV9 has emerged as the most widely used for CNS gene therapy applications due to its enhanced spread across CNS structures and its ability to penetrate the BBB even after peripheral administration in neonatal animals [61,62].”
BackgroundInfluentialAdeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“These CNS-directed delivery strategies, however, are not enough to completely prevent the effect of circulating anti-AAV antibodies and delivery strategies can physically disrupt the BBB allowing even greater access for circulating antibodies to enter the brain and neutralize the vector [39,48].”
BackgroundLong-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.220 · Cited by 298 · cited 1×
“A Phase I trial using bilateral injections of AAV2-AADC into the putamen of PD patients was well tolerated and resulted in improved AADC expression and motor function one-year post-dosing [84].”
BackgroundMeyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286 · cited 5×
“AVXS-101 is already approved in the US as Zolgensma for systemic use in the treatment of SMA.”
BackgroundResultInfluentialManufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286 · cited 1×
“Advances in vector design [10–13], manufacturing technology [14], and the addition of immunomodulatory treatments to clinical protocols [6,15,16] have focused on controlling immunogenicity of the virus and host immune response to therapy [17–19].”
BackgroundCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 1×
“First, experiments comparing AAV-treated TLR9 knockout (TLR9-/-) and wild type mice support the direct involvement of the TLR9 pathway in immune activation and transgene loss [10].”
MethodCerebrospinal fluid and lumbar puncture: a practical review
Wright, B. L. C., Lai, J. T. F., & Sinclair, A. J. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6413-x · Cited by 250 · cited 1×
“CSF is generated by the choroid plexus in the lateral ventricles, and flows downward through the third and fourth ventricles, down to the lumbar cistern in the spinal cord [81].”
BackgroundMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · cited 1×
“reported another contributing factor to the extent of the TLR9-dependent response to the AAV genome—that single stranded DNA viral genomes are less immunoreactive than double stranded (self-complementary) viral genomes when tested with intravenous injections in mice [87].”
BackgroundNeuroinflammation: Ways in Which the Immune System Affects the Brain
Ransohoff, R. M., Schafer, D., Vincent, A., Blachère, N. E., & Bar-Or, A. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0385-3 · Cited by 243 · cited 1×
“…oligodendrocytes), peripheral immune cell infiltrates (T cells), breakdown of the blood–brain barrier, pro-inflammatory cytokines and other mechanisms (for detailed reviews on cell types and mechanisms associated with neuroinflammation, see Ransohoff et al. 2010, 2012, 2015, 2016) [24,27–29].”
BackgroundImmune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241 · cited 4×
“Finally, although intraparenchymal injections are more invasive [9,82] and result in a limited coverage of the CNS, this approach is likely immunologically safest, requiring the least amount of virus to reach clinically relevant transgene expression if target tissues are few and easy to isolate.”
BackgroundInfluentialPerdomini, M., Belbellaa, B., Monassier, L., Reutenauer, L., Messaddeq, N., Cartier, N., Crystal, R. G., Aubourg, P., & Puccio, H. (2014) · Nature Medicine · doi:10.1038/nm.3510 · Cited by 239
Zand, M. S., Vo, T., Huggins, J., Felgar, R., Liesveld, J., Pellegrin, T., Bozorgzadeh, A., Sanz, I., & Briggs, B. J. (2005) · Transplantation · doi:10.1097/01.tp.0000164159.20075.16 · Cited by 237 · cited 1×
“Plasma cells are highly resistant to most currently available immunosuppressive strategies, with stem cell transplants with anti-thymocyte globulin treatment being the most effective but presenting significant safety risk to patients [96,99,100].”
BackgroundAutologous stem cell transplantation for systemic lupus erythematosus
Jayne, D., & Tyndall, A. (2004) · Lupus · doi:10.1191/0961203304lu1027oa · Cited by 225 · cited 1×
“Plasma cells are highly resistant to most currently available immunosuppressive strategies, with stem cell transplants with anti-thymocyte globulin treatment being the most effective but presenting significant safety risk to patients [96,99,100].”
BackgroundPeden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222 · cited 2×
“These CNS-directed delivery strategies, however, are not enough to completely prevent the effect of circulating anti-AAV antibodies and delivery strategies can physically disrupt the BBB allowing even greater access for circulating antibodies to enter the brain and neutralize the vector [39,48].”
BackgroundCapsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain
Chakrabarty, P., Rosario, A., Cruz, P., Siemienski, Z., Ceballos-Diaz, C., Crosby, K., Jansen, K., Borchelt, D. R., Kim, J.-Y., Jankowsky, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067680 · Cited by 207
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 2×
“In a study of 10 subjects undergoing plasmapheresis, anti-capsid nAbs against AAV serotypes 1, 2, 6, and 8 were measured before and after each treatment [95].”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Fu, H., DiRosario, J., Killedar, S., Zaraspe, K., & McCarty, D. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.34 · Cited by 197 · cited 3×
“Systemic administration of AAV9 at doses of 2–5 × 1013 vg/kg is being employed in ongoing clinic trials of MPS IIIB (NCT03315182) and MPS IIIA (NCT04088734) with the release of safety and efficacy data unavailable at the time that this review was written.”
ResultInfluence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192 · cited 1×
“Systemic delivery (as well as natural environmental exposure) of high vector doses will result in circulating anti-capsid and anti-transgene binding antibodies (bAb) and capsid-neutralizing antibodies (nAb), priming the immune system to detect and neutralize future exposures to the virus, presenting additional immune-…”
BackgroundTLR2 and TLR9 Synergistically Control Herpes Simplex Virus Infection in the Brain
Sørensen, L. N., Reinert, L. S., Malmgaard, L., Bartholdy, C., Thomsen, A. R., & Paludan, S. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8604 · Cited by 183 · cited 1×
“TLR9 has been implicated in mediating the innate immune response to herpes simplex virus infection in the brain [92] as well as in pathobiology of several neurodegenerative diseases [91,93].”
BackgroundKruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182 · cited 1×
“The currently accepted exclusion criteria leaves out 20–70% of otherwise eligible patients [3,44].”
BackgroundCurrent perspectives on intrathecal drug delivery
Christo, P., & Bottros, M. (2014) · Journal of Pain Research · doi:10.2147/jpr.s37591 · Cited by 174
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167 · cited 2×
“In contrast to the clinical findings summarized above, this preclinical study reports that the nAb titers were reduced to levels similar to the naïve animals after only two treatments in all seven NHP models treated [96].”
BackgroundResultSchuster, D. J., Dykstra, J. A., Riedl, M. S., Kitto, K. F., Belur, L. R., McIvor, R. S., Elde, R. P., Fairbanks, C. A., & Vulchanova, L. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00042 · Cited by 161 · cited 3×
“For example, experiments comparing equivalent doses of AAV9 (total vg exposure) administered either systemically or directly into the CSF resulted in dramatically enhanced transduction efficacy in CNS and sensory neurons in direct CSF delivery compared to systemically administered vector [58].”
BackgroundInfluentialIntracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration
Cohen-Pfeffer, J. L., Gururangan, S., Lester, T., Lim, D. A., Shaywitz, A. J., Westphal, M., & Slavc, I. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.10.022 · Cited by 160 · cited 1×
“Although this technique is relatively safe and effective, and is routinely undertaken by neurosurgeons [75], it is not without risks and complications including infections, intracerebral hemorrhage, subcutaneous CSF leaks and increased intracranial pressure [75–78].”
BackgroundLowenstein, P., Mandel, R., Xiong, W.-D., Kroeger, K., & Castro, M. (2007) · Current Gene Therapy · doi:10.2174/156652307782151498 · Cited by 157 · cited 1×
“However, recent gene therapy studies for CNS disorders reveal a significant involvement of the immune system in the brain [23,24] and unexpected immune reactions have been reported in several studies of AAV delivery directly into the CNS compartment [25,26].”
BackgroundBiology of adeno-associated viral vectors in the central nervous system
Murlidharan, G., Samulski, R. J., & Asokan, A. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00076 · Cited by 154
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140 · cited 3×
“A single subject case report by our group showed that immune modulation with rituximab and rapamycin prior to AAV administration blocked antibody-based immune responses to both capsid and transgene [15].”
BackgroundSelf-citationFerreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137
Ellinwood, N. M., Ausseil, J., Desmaris, N., Bigou, S., Liu, S., Jens, J. K., Snella, E. M., Mohammed, E. E., Thomson, C. B., Raoul, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.265 · Cited by 137 · cited 2×
“Numerous preclinical studies of CNS-directed AAV administration have reported circulating nAbs against the vector capsid and elevated markers of cytotoxicity [20,25,49,50].”
BackgroundHinderer, C., Bell, P., Vite, C. H., Louboutin, J.-P., Grant, R., Bote, E., Yu, H., Pukenas, B., Hurst, R., & Wilson, J. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.51 · Cited by 129 · cited 1×
“reported significant transgene expression at comparable levels across cortex, hippocampus, medulla, cerebellum, and spinal cord regions [79].”
BackgroundGoldshmit, Y., Kanner, S., Zacs, M., Frisca, F., Pinto, A. R., Currie, P. D., & Pinkas‐Kramarski, R. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.04.006 · Cited by 122 · cited 1×
“A study using in vitro and mouse models of spinal cord injury shows that treatment with rapamycin results in neuronal survival, reduced inflammation, and astrocyte proliferation after spinal cord injury [102].”
BackgroundAdeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
Self-citationCorti, M., Liberati, C., Smith, B. K., Lawson, L. A., Tuna, I. S., Conlon, T. J., Coleman, K. E., Islam, S., Herzog, R. W., Fuller, D. D., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.146 · Cited by 120
Self-citationMicroglia-specific targeting by novel capsid-modified AAV6 vectors
Rosario, A. M., Cruz, P. E., Ceballos-Diaz, C., Strickland, M. R., Siemienski, Z., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G. V., Srivastava, A., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.26 · Cited by 118
Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future
Piguet, F., Alves, S., & Cartier, N. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.160 · Cited by 109
Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I
Hinderer, C., Bell, P., Gurda, B. L., Wang, Q., Louboutin, J.-P., Zhu, Y., Bagel, J., O'Donnell, P., Sikora, T., Ruane, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.135 · Cited by 108 · cited 1×
“On the other hand, many studies have shown no evidence of neuroinflammation [1,52,53], highlighting the need to compare experimental designs including the appropriateness of a large animal model in preclinical trials and biomarker selection across preclinical and clinical trials.”
BackgroundHordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.003 · Cited by 105 · cited 4×
“Numerous preclinical studies of CNS-directed AAV administration have reported circulating nAbs against the vector capsid and elevated markers of cytotoxicity [20,25,49,50].”
BackgroundResultInfluentialGadalla, K. K. E., Vudhironarit, T., Hector, R. D., Sinnett, S., Bahey, N. G., Bailey, M. E. S., Gray, S. J., & Cobb, S. R. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.007 · Cited by 103
Spronck, E. A., Brouwers, C. C., Vallès, A., de Haan, M., Petry, H., van Deventer, S. J. H., Konstantinova, P. S., & Evers, M. M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.002 · Cited by 96 · cited 1×
“Recent work suggests that microglia may also form an immunological memory similar to plasma cells [83], suggesting that long-lived immunological memory may be a concern within the CNS compartment as well.”
BackgroundErtl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Murrey, D. A., Naughton, B. J., Duncan, F. J., Meadows, A. S., Ware, T. A., Campbell, K. J., Bremer, W. G., Walker, C. M., Goodchild, L., Bolon, B., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.208 · Cited by 88 · cited 2×
“achieved transgene expression within the CNS after systemic injections of 1 × 1013 or 2 × 1013 vg/kg [41].”
BackgroundGolebiowski, D., van der Bom, I. M. J., Kwon, C.-S., Miller, A. D., Petrosky, K., Bradbury, A. M., Maitland, S., Kühn, A. L., Bishop, N., Curran, E., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.109 · Cited by 87 · cited 3×
“Another preclinical study in a NHP model using a combination of intracerebroventricular (ICV) and bilateral intraparenchymal injections of AAV rh8 into the thalamus reported neurotoxicity and associated behavioral changes [25].”
BackgroundIn vivo Imaging of Glial Activation in Alzheimer's Disease
Edison, P., Donat, C. K., & Sastre, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00625 · Cited by 86
Gene therapy of the brain in the dog model of Hurler's syndrome
Ciron, C., Desmaris, N., Colle, M.-A., Raoul, S., Joussemet, B., Vérot, L., Ausseil, J., Froissart, R., Roux, F., Chérel, Y., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20870 · Cited by 85 · cited 2×
“Finally, studies using dog models of Sanfilippo and Hurler syndrome used intraparenchymal delivery of AAV vector and reported neuroinflammation including lymphocyte, plasma cells, and macrophage infiltration into perivascular and subarachnoid spaces with diffuse hyperplasia and clusters of microglia [49].”
BackgroundResultElder, M. E., Nayak, S., Collins, S. W., Lawson, L. A., Kelley, J. S., Herzog, R. W., Modica, R. F., Lew, J., Lawrence, R. M., & Byrne, B. J. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.03.002 · Cited by 81 · cited 1×
“Additionally, patients with null mutations where the immune system is naïve to endogenous protein, also known as cross-reactive immunological material-negative (CRIM-) patients, perceive the AAV-derived transgene as immunologically foreign and develop higher antibody levels and more severe T-cell responses against the…”
BackgroundSelf-citationHordeaux, J., Hinderer, C., Goode, T., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.004 · Cited by 81 · cited 1×
“However, preclinical studies in large animal models detect AAV-related markers of neuroinflammation and CNS pathology even after CNS-specific delivery methods [20,21], suggesting that the issue of host immune responses to the vector is not exclusive to systemic dosing strategies.”
BackgroundBest practices for the use of intracerebroventricular drug delivery devices
Slavc, I., Cohen-Pfeffer, J. L., Gururangan, S., Krauser, J., Lim, D. A., Maldaun, M., Schwering, C., Shaywitz, A. J., & Westphal, M. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.05.003 · Cited by 77
Ayers, J. I., Fromholt, S., Sinyavskaya, O., Siemienski, Z., Rosario, A. M., Li, A., Crosby, K. W., Cruz, P. E., DiNunno, N. M., Janus, C., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.180 · Cited by 76 · cited 1×
“Studies in animal models of SMA [42], amyotrophic lateral sclerosis (ALS) [63], MPS IIIB [64], and others show that a systemic injection of AAV9 in neonatal mice results in transgene expression across key CNS substructures and neuronal subtypes such as motoneurons along with improvements in disease-related phenotypes.”
ResultAAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials
Hardcastle, N., Boulis, N. M., & Federici, T. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1416089 · Cited by 70 · cited 1×
“Finally, although intraparenchymal injections are more invasive [9,82] and result in a limited coverage of the CNS, this approach is likely immunologically safest, requiring the least amount of virus to reach clinically relevant transgene expression if target tissues are few and easy to isolate.”
BackgroundLong-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses
Holt, P. G., Sedgwick, J. D., O'Leary, C., Krska, K., & Leivers, S. (1984) · Cellular Immunology · doi:10.1016/0008-8749(84)90330-7 · Cited by 60 · cited 1×
“In addition to managing systemically circulating antibodies, difficult to eliminate long-lived plasma cells may be reactivated by AAV treatment, secreting additional antibodies [97,98].”
BackgroundTLR7 and TLR9 Trigger Distinct Neuroinflammatory Responses in the CNS
Butchi, N. B., Woods, T. A., Du, M., Morgan, T. W., & Peterson, K. E. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.011 · Cited by 59 · cited 1×
“proinflammatory cytokines and chemokines, a breakdown of the BBB, and infiltration of immune cells from the periphery [94].”
BackgroundRibera, A., Haurigot, V., Garcia, M., Marcó, S., Motas, S., Villacampa, P., Maggioni, L., León, X., Molas, M., Sánchez, V., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu727 · Cited by 53 · cited 1×
“On the other hand, many studies have shown no evidence of neuroinflammation [1,52,53], highlighting the need to compare experimental designs including the appropriateness of a large animal model in preclinical trials and biomarker selection across preclinical and clinical trials.”
BackgroundTargeted approaches to induce immune tolerance for Pompe disease therapy
Doerfler, P. A., Nayak, S., Corti, M., Morel, L., Herzog, R. W., & Byrne, B. J. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.53 · Cited by 51 · cited 1×
“Additionally, patients with null mutations where the immune system is naïve to endogenous protein, also known as cross-reactive immunological material-negative (CRIM-) patients, perceive the AAV-derived transgene as immunologically foreign and develop higher antibody levels and more severe T-cell responses against the…”
BackgroundSelf-citationDecreased carbon-11-flumazenil binding in early Alzheimer’s disease
Pascual, B., Prieto, E., Arbizu, J., Marti-Climent, J. M., Peñuelas, I., Quincoces, G., Zarauza, R., Pappatà, S., & Masdeu, J. C. (2012) · Brain · doi:10.1093/brain/aws210 · Cited by 45 · cited 1×
“Additionally, functional imaging can be used to monitor the activation of resident immune cells and begin to understand the mechanisms behind gene therapy-related neuroinflammation [35,36].”
BackgroundPetrosyan, H. A., Alessi, V., Singh, V., Hunanyan, A. S., Levine, J. M., & Arvanian, V. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.74 · Cited by 44
Vuillemenot, B. R., Korte, S., Wright, T. L., Adams, E. L., Boyd, R. B., & Butt, M. T. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw072 · Cited by 38
3′UTRs take a long shot in the brain
Wang, L., & Yi, R. (2013) · BioEssays · doi:10.1002/bies.201300100 · Cited by 33
Assessment of Blood Brain Barrier Leakage with Gadolinium-Enhanced MRI
Ku, M., Waiczies, S., Niendorf, T., & Pohlmann, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7531-0_23 · Cited by 33 · cited 1×
“For example, magnetic resonance imaging (MRI) could be utilized to evaluate inflammation-related neuropathology such as white matter changes, ventricular enlargement [33], or cell death, and BBB breakdown by measuring leakage of gadolinium to the periphery [34].”
BackgroundEnlargement of Cerebral Ventricles as an Early Indicator of Encephalomyelitis
Lepore, S., Waiczies, H., Hentschel, J., Ji, Y., Skodowski, J., Pohlmann, A., Millward, J. M., Paul, F., Wuerfel, J. T., Niendorf, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072841 · Cited by 31 · cited 1×
“For example, magnetic resonance imaging (MRI) could be utilized to evaluate inflammation-related neuropathology such as white matter changes, ventricular enlargement [33], or cell death, and BBB breakdown by measuring leakage of gadolinium to the periphery [34].”
BackgroundKarman, J., Gumlaw, N. K., Zhang, J., Jiang, J.-L., Cheng, S. H., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034684 · Cited by 25 · cited 1×
“Pre-treatment with plasma cell-targeting agents such as bortezomib might be useful in depleting the plasma cell population and decreasing reactivation upon subsequent AAV exposure [3,101].”
BackgroundSamaranch, L., Bringas, J., Pivirotto, P., Sebastián, W. S., Forsayeth, J., & Bankiewicz, K. S. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.129 · Cited by 24 · cited 1×
“However, this approach is rarely utilized in clinical practice and would need significant procedural development to safely enter clinical trials due to the route’s increased risk for medullary injury and related complications [80].”
Method
Research works printed but not linked: 9
- Corti M. Norman S. Coleman K. Liberati C. Elder M. Escolar M. Clement N. Clever B. Byrne B. Gao G. Immune Blockade in CNS Gene Therapy Improves Safety and Clinical Outcome Molecular Therapy Cell Press Cambridge, MA, USA 2018 Volume 26 32
- Nair J. Freeman D. Jr. Davis I. McParland T. Pope M. Perez B. Rodriguez-Lebron E. Coleman K. Subramony S. Byrne B. AAV9 Biodistribution with Different Routes of CNS Administration in Rodents Molecular Therapy Cell Press Cambridge, MA, USA 2019 Volume 27 259
- Perez B.A. Coleman K.E. Wichman M.B. Futch K.N. Mandolini K.E. Cravey L.D. Nair J. Cloutier D.A. Lynch D. Byrne B.J. Management of Preexisting Immunity to AAV9 in Friedreich’s Ataxia Molecular Therapy Cell Press Cambridge, MA, USA 2019 Volume 27 140
- Letizia A. Chan Y.K. Graveline A. Church G. Engineering AAV Vectors to Reduce CD8+ T Cell Responses Following Intramuscular Injection in Mice Molecular Therapy Cell Press Cambridge, MA, USA 2019 Volume 27 301
- Chan Y.K. Wang S. Letizia A. Chan Y. Lim E. Graveline A. Verdera H.C. Alphonse P. Xue Y. Chiang J. Reducing AAV-Mediated Immune Responses and Pathology in a Subretinal Pig Model by Engineering the Vector Genome Molecular Therapy Cell Press Cambridge, MA, USA 2019 Volume 27 298
- Saade D. Bhurucha-Goebel D. Foley A.R. Neuhaus S.B. Soldatos A. Hu Y. Hewitt M. Calcedo del Hoyo R. Jacobson S. Liebovitch E. Review of CSF and Peripheral Immune Responses Following Intrathecal Gene Transfer for Giant Axonal Neuropathy Molecular Therapy Cell Press Cambridge, MA, USA 2018 Volume 26 456 457
- Bharucha-Goebel D. Saade D. Soldatos A. Kang E. Del Calcedo R. Hu Y. Liebovitch E. Jacobson S. Rybin D. Foley A.R. Immune Analysis Following Intrathecal Gene Transfer: 3-Year Data from Clinical Intrathecal Gene Transfer Trial for Patients with Giant Axonal Neuropathy Molecular Therapy Cell Press Cambridge, MA, USA 2019 Volume 27 298 299
- Kuntz N. Shieh P.B. Smith B. Bonnemann C.G. Dowling J.J. Lawson M.W. Muller-Felber W. Noursalehi M. Rico S. Servais L. Aspiro Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (Xlmtm): Preliminary Safety and Efficacy Findings Molecular Therapy Cell Press Cambridge, MA, USA 2018 Volume 26 4
- Pfizer Presents Initial Clinical Data on Phase 1B Gene Therapy Study for Duchenne Muscular Dystrophy (DMD) Available online: https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Presents-Initial-Clinical-Data-on-Phase-1b-Gene-Therapy-Study-for-Duchenne-Muscular-Dystrophy-DMD/default.aspx (accessed on 28 January 2020)
Cited by
Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology
Hordeaux, J., Buza, E. L., Dyer, C., Goode, T., Mitchell, T. W., Richman, L., Denton, N., Hinderer, C., Katz, N., Schmid, R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.167 · Cited by 257
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“Mutation status may affect the risk of an immune response, given that those with null mutations (cross-reactive immunological material [CRIM] negative) are more likely to recognize the transgenic protein as foreign and develop more severe antibody andT cell responses than individualswho express the endogenous protein…”
BackgroundNovel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“…combined with other technologies, such as rational design-based modification of immunogenic residues at the capsid surface or optimisation of the 12 of 19 EMBO Molecular Medicine 13: e13392 | 2021 ª 2021 The Authors AAV2 genome in order to mitigate any risk of immune responses (Perez et al, 2020).”
Metadata
- Authors
- Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M.
- Affiliations
- University of Florida (US)
- AavantiBio, Inc., Gainesville, FL 32601, USA
- Harvard University (US)
- Corresponding author
- Corti, Manuela
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2020-02-22
- Volume
- 10
- Issue
- 2
- Pages
- 119
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC7071492
- OpenAlex
- W3007981561
- Cited by
- 112
- References
- 92
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 14 · 2022: 29 · 2021: 21 · 2020: 7
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5T32DK074367-04)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, AAV gene therapy, neuroinflammation, neurodegenerative diseases, spinal muscular atrophy, Canavan disease, Parkinson's disease, Friedreich's ataxia, immunosuppression, dorsal root ganglia, myelopathy, mononuclear cell infiltration, neuroinflammation biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.